PT Prodia Widyahusada (PRDA) Fundamentals 2026 — P/E 10.0x, Revenue Analysis | SniperIQ
PT Prodia Widyahusada (PRDA) is a ID-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of Rp2.13T, trading at Rp2390.00 on the JKT. This SniperIQ fundamentals page covers PT Prodia Widyahusada's valuation (P/E 10.0x, P/B 0.9x), profitability (net margin 9.4%), revenue (Rp2.28T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Prodia Widyahusada's market cap?
PT Prodia Widyahusada (PRDA) has a market capitalization of approximately Rp2.13T, trading at Rp2390.00 on the JKT. Market cap moves with the live share price.
What is PT Prodia Widyahusada's P/E ratio?
PT Prodia Widyahusada's trailing twelve-month P/E ratio is 10.0x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Prodia Widyahusada?
PT Prodia Widyahusada runs a net profit margin of 9.4%, a gross margin of 54.0%, and an operating margin of 10.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Prodia Widyahusada generate?
PT Prodia Widyahusada reported revenue of Rp2.28T for fiscal year 2025, with net income of Rp206.8B and earnings per share (EPS) of 227.25. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Prodia Widyahusada pay a dividend?
PT Prodia Widyahusada offers a trailing dividend yield of about 6.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PT Prodia Widyahusada financially healthy?
PT Prodia Widyahusada carries a debt-to-equity ratio of 0.01x and a current ratio of 6.44x, with a market beta of -0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Prodia Widyahusada a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Prodia Widyahusada (PRDA) the key facts are: market cap Rp2.13T, P/E 10.0x, revenue Rp2.28T, 52-week range 2230-3010. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Prodia Widyahusada's full fundamentals live
Get PT Prodia Widyahusada's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.